INAFM2: A Potential Drug Target and Biomarker (G100505573)

Target Name: INAFM2

NCBI ID: G100505573

INAFM2

INAFM2: A Potential Drug Target and Biomarker

INAFM2, also known as interleukin-2 receptor alpha chain, is a protein that plays a crucial role in the immune system. It is a member of the interleukin-2 receptor family, which includes several different proteins that regulate the activity of T cells, B cells, and natural killer cells. INAFM2 is expressed in a variety of tissues and cells throughout the body, including the skin, hair, and nervous system.

The discovery and characterization of INAFM2 as a potential drug target and biomarker has significant implications for the development of new treatments for a variety of diseases. INAFM2 has been shown to be involved in a wide range of physiological processes, including immune regulation, inflammation, and tissue repair. As such, it is a promising target for small molecule inhibitors and other therapeutic agents that can modulate its activity.

Drug Target Interaction with INAFM2

INAFM2 is a protein that is expressed in a variety of tissues and cells throughout the body, including the skin, hair, and nervous system. It is a member of the interleukin-2 receptor family, which includes several different proteins that regulate the activity of T cells, B cells, and natural killer cells. INAFM2 is expressed in high levels in the skin, and it has been shown to play a role in the regulation of skin cell proliferation and differentiation.

Recent studies have shown that INAFM2 is involved in a wide range of physiological processes, including immune regulation, inflammation, and tissue repair. It is a potential drug target because of its involvement in these processes, as well as its unique structure and expression patterns.

One of the key features of INAFM2 is its extracellular domain. This domain is involved in the interaction between INAFM2 and other proteins, including cell signaling pathways. It is known that INAFM2 can interact with the protein PD-L1, which is a negative regulator of the T cell response. This interaction between INAFM2 and PD-L1 has significant implications for the regulation of immune responses.

In addition to its interaction with PD-L1, INAFM2 has also been shown to interact with several other proteins, including the transcription factor NF-kappa-B. This interaction between INAFM2 and NF-kappa-B suggests that INAFM2 may be involved in the regulation of cellular processes that are influenced by NF-kappa-B signaling.

Biomarker Potential

The characterization of INAFM2 as a potential drug target and biomarker has significant implications for the development of new treatments for a variety of diseases. INAFM2 has been shown to be involved in a wide range of physiological processes, including immune regulation, inflammation, and tissue repair. As such, it is a promising target for small molecule inhibitors and other therapeutic agents that can modulate its activity.

One potential approach to the treatment of INAFM2-related diseases is the use of small molecule inhibitors that can modulate the activity of INAFM2. These inhibitors could be used to treat a variety of diseases, including autoimmune diseases, inflammatory diseases, and wound healing disorders.

Another approach to the treatment of INAFM2-related diseases could be the use of antibodies that are specifically designed to target INAFM2. These antibodies could be used to treat a variety of diseases, including autoimmune diseases, inflammatory diseases, and cancer.

Conclusion

INAFM2 is a protein that plays a crucial role in the immune system. Its unique structure and expression patterns make it a promising target for small molecule inhibitors and other therapeutic agents that can modulate its activity. Further research is needed to fully understand the role of INAFM2 in

Protein Name: InaF Motif Containing 2

The "INAFM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INAFM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets